menu
    • menu

    Company profile for Immuneering Corporation

    NEW Drugs in Dev: 3
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Immuneering leverages more than a decade of leadership in bioinformatics to develop new medicines unlikely to be found by traditional drug discovery methods. Its current pipeline of drug candidates is focused on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. Utilizing its proprietary Disease Cancelling Technology, the company engineers medicines that reverse a di...
    Immuneering leverages more than a decade of leadership in bioinformatics to develop new medicines unlikely to be found by traditional drug discovery methods. Its current pipeline of drug candidates is focused on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. Utilizing its proprietary Disease Cancelling Technology, the company engineers medicines that reverse a disease signal across many relevant genes. Immuneering’s technologies have proven exceptionally rapid and capital-efficient in creating its pipeline.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Immuneering CorporationUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    245 Main St, Second Floor Cambridge, MA 02142
    Telephone
    Telephone
    (617) 500-8080
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://immuneering.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/immuneering-corporation
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/immuneering

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASCO GU

    ASCO GU

    Not Confirmed

    envelop Contact Supplier

    ASCO GU

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immuneering To Present At Oppenheimer Healthcare Life Sciences
    Immuneering To Present At Oppenheimer Healthcare Life Sciences

    18 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/18/3240615/0/en/Immuneering-to-Present-at-the-Oppenheimer-36th-Annual-Healthcare-Life-Sciences-Conference.html

    GLOBENEWSWIRE
    18 Feb 2026
    Share Share
    Immuneering Touts 64% Survival, Fueling Race With Revolution
    Immuneering Touts 64% Survival, Fueling Race With Revolution

    08 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/immuneering-touts-64-1-year-survival-keeping-wheels-turning-race-revolution

    FIERCE BIOTECH
    08 Jan 2026
    Share Share
    Immuneering Reports 64% 12-Month Survival in Pancreatic Cancer
    Immuneering Reports 64% 12-Month Survival in Pancreatic Cancer

    07 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/07/3214881/0/en/Immuneering-Announces-Exceptional-64-Overall-Survival-At-12-Months-in-First-Line-Pancreatic-Cancer-Patients-Treated-with-Atebimetinib-mGnP.html

    GLOBENEWSWIRE
    07 Jan 2026
    Share Share
    Immuneering Announces 12-Month OS Data From Atebimetinib Trial
    Immuneering Announces 12-Month OS Data From Atebimetinib Trial

    23 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/23/3209839/0/en/Immuneering-to-Announce-12-Month-Overall-Survival-Data-from-Phase-2a-Clinical-Trial-of-Atebimetinib-mGnP-in-First-Line-Pancreatic-Cancer-Patients-on-January-7-2026.html

    GLOBENEWSWIRE
    23 Dec 2025
    Share Share
    Immuneering Aligns with FDA, EMA on Atebimetinib Phase 3 Trial
    Immuneering Aligns with FDA, EMA on Atebimetinib Phase 3 Trial

    17 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/17/3207312/0/en/Immuneering-Advances-Towards-Dosing-First-Patient-in-Phase-3-Atebimetinib-Trial-for-First-Line-Metastatic-Pancreatic-Cancer-Patients-Securing-Alignment-with-FDA-and-EMA.html

    GLOBENEWSWIRE
    17 Dec 2025
    Share Share
    Immuneering To Be Added To The Nasdaq Biotechnology Index (NBI)
    Immuneering To Be Added To The Nasdaq Biotechnology Index (NBI)

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3206181/0/en/Immuneering-to-be-Added-to-the-Nasdaq-Biotechnology-Index-NBI.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search